CureMatch

CureMatch, Inc. is a San Diego-based digital health company focused on personalized medicine and combination therapy in oncology. Its Decision Support System guides oncologists in the selection of cancer drugs customized for individual patients based on their molecular tumor profiles, enabling care teams to become experts in precision medicine by delivering actionable intelligence toward advanced cancer treatment options.

CureMatch serves oncologists, cancer centers, next-generation sequencing (NGS) labs, concierge medicine providers, BioPharma organizations, and employers — as well as the patients they support. The platform leverages advanced proprietary algorithms and extensive curation of genomic, historical, and patient-specific data to calculate, rank, and score genomically matched combination treatment options. Clinical evidence supporting the approach includes the landmark I-PREDICT study (Nature Medicine, Kurzrock 2019), which demonstrated that progression-free survival was significantly improved in 75% of patients treated with combination therapies based on high matching scores of targeted treatment options.

Core Decision Support Capabilities

• Calculates and ranks combinations of genomically matched cancer treatments tailored to each patient's unique molecular tumor profile, regardless of the diagnosed cancer type
• Delivers a clear, structured report layout of ranked combination drug therapies targeting a patient's cancer at the genomic level, providing actionable knowledge for oncologists and care teams
• Processes and synthesizes data that would otherwise take days to manually sort through, covering the latest FDA-approved drugs and their potential combinations
• Provides predictive treatment analysis designed to equip oncologists with customized, case-specific insights for upcoming cancer drug treatment decisions

Targeted Proteomics

• Incorporates proteomic data alongside genomic data derived from FFPE tissue samples to provide an additional molecular-level profile of a patient's cancer
• Enables a fuller understanding of the biology of a patient's cancer to help determine the optimal treatment for that individual's unique cancer
• Combines proteomic and genomic profiling to support more comprehensive and personalized combination therapy analysis

CPT Code and Reimbursement

• CureMatch has been granted CPT Code 0794T by the American Medical Association (AMA), a Category III code for its therapy matching and scoring service
• The code covers a patient-specific, assistive, rules-based algorithm for ranking pharmaco-oncologic treatment options based on tumor-specific cancer marker information obtained from prior molecular pathology, immunohistochemical, or other pathology results
• Published by the AMA on January 1, 2023, and effective July 1, 2023, the code allows oncologists to track use of the CureMatch system and submit claims to payers for reimbursement, paving the way for wider adoption of precision treatment options

Leadership, Advisors, and Compliance

• Co-founded by Razelle Kurzrock, MD, a leading oncology researcher and Chief Medical Advisor, alongside Blaise Barrelet as Co-Founder and Board Director
• Led by CEO Navid Alipour (JD/MBA), Chief Science Officer Ally Perlina, and a board chaired by life sciences executive David Szekeres
• Supported by an extensive advisory network including clinicians and researchers from UC San Diego Health, Johns Hopkins Hospital, Yale Cancer Center, Memorial Care, and other leading institutions, as well as industry executives from BioPharma, medtech, and digital health sectors
• Operates in compliance with HIPAA and maintains a formal Privacy Policy and Terms of Use, reflecting its commitment to data security and patient privacy in a clinical decision support context

CureMatch represents a new era in patient care, bringing the power of precision medicine to oncology practices through scientifically validated, algorithmically driven combination therapy analysis that helps clinicians make better-informed treatment decisions for each individual patient.